1) To develop diagnostic markers of the “p73 pathway status” that could predict whether a p73-activating therapy would be appropriate in a given tumor and perhaps to direct the choice of which upstream p73 modulator should be targeted by a new generation of pathway-tailored drugs. Here, TP73 is linked to neoplasm.